Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches.
Versteven M, Van den Bergh JMJ, Broos K, Fujiki F, Campillo-Davo D, De Reu H, Morimoto S, Lecocq Q, Keyaerts M, Berneman Z, Sugiyama H, Van Tendeloo VFI, Breckpot K, Lion E. Versteven M, et al. Among authors: breckpot k. Oncotarget. 2018 Jun 12;9(45):27797-27808. doi: 10.18632/oncotarget.25591. eCollection 2018 Jun 12. Oncotarget. 2018. PMID: 29963238 Free PMC article.
Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D: -luciferin: effect on intensity, time kinetics and repeatability of photon emission.
Keyaerts M, Verschueren J, Bos TJ, Tchouate-Gainkam LO, Peleman C, Breckpot K, Vanhove C, Caveliers V, Bossuyt A, Lahoutte T. Keyaerts M, et al. Among authors: breckpot k. Eur J Nucl Med Mol Imaging. 2008 May;35(5):999-1007. doi: 10.1007/s00259-007-0664-2. Epub 2008 Jan 4. Eur J Nucl Med Mol Imaging. 2008. PMID: 18180921
Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo.
Benteyn D, Anguille S, Van Lint S, Heirman C, Van Nuffel AM, Corthals J, Ochsenreither S, Waelput W, Van Beneden K, Breckpot K, Van Tendeloo V, Thielemans K, Bonehill A. Benteyn D, et al. Among authors: breckpot k. Mol Ther Nucleic Acids. 2013 Nov 19;2(11):e134. doi: 10.1038/mtna.2013.54. Mol Ther Nucleic Acids. 2013. PMID: 24253259 Free PMC article.
Immunogenicity of targeted lentivectors.
Goyvaerts C, Kurt de G, Van Lint S, Heirman C, Van Ginderachter JA, De Baetselier P, Raes G, Thielemans K, Breckpot K. Goyvaerts C, et al. Among authors: breckpot k. Oncotarget. 2014 Feb 15;5(3):704-15. doi: 10.18632/oncotarget.1680. Oncotarget. 2014. PMID: 24519916 Free PMC article.
The ReNAissanCe of mRNA-based cancer therapy.
Van Lint S, Renmans D, Broos K, Dewitte H, Lentacker I, Heirman C, Breckpot K, Thielemans K. Van Lint S, et al. Among authors: breckpot k. Expert Rev Vaccines. 2015 Feb;14(2):235-51. doi: 10.1586/14760584.2015.957685. Epub 2014 Sep 29. Expert Rev Vaccines. 2015. PMID: 25263094 Review.
Targeting the tumor microenvironment to enhance antitumor immune responses.
Van der Jeught K, Bialkowski L, Daszkiewicz L, Broos K, Goyvaerts C, Renmans D, Van Lint S, Heirman C, Thielemans K, Breckpot K. Van der Jeught K, et al. Among authors: breckpot k. Oncotarget. 2015 Jan 30;6(3):1359-81. doi: 10.18632/oncotarget.3204. Oncotarget. 2015. PMID: 25682197 Free PMC article. Review.
151 results